Clinical Trials
Macquarie University is a public research university based in Sydney, Australia, in the suburb of Macquarie Park. Founded in 1964 by the New South Wales Government, it was the third university to be established in the metropolitan area of Sydney.
Woke and Macquarie University have entered an agreement to conduct a ground-breaking Phase IIB trial of Woke’s novel low-dose (microdose) psilocybin, WP001, to treat moderate depression. The Principal Investigator, Dr Vince Polito, a Senior Research Fellow in the Department of Cognitive Science at Macquarie University, has focused much of his work on investigating the ways that altered states and, in particular, psychedelics might impact consciousness and cognition. Dr Polito is a leading researcher in the field of psychedelic microdosing. He has assembled a first-rate team of experts to support the trial.
“Macquarie University's Dr Polito is a leading clinician in the field of microdosing psilocybin and has assembled an exceptional interdisciplinary team that includes several of the most experienced psychedelic researchers within Australia, to conduct this Phase IIB trial of Woke’s WP001 for treatment of moderate depression.”
Curtin University is Western Australia’s largest university, with close to 60,000 students. Curtin staff and students come from Australia and over 120 other countries around the world, with half their international students studying at Curtin’s offshore campuses. Curtin is ranked in the top one per cent of universities worldwide.
Woke and Curtin University in collaboration with Monash University and the George Institute are conducting a randomised controlled trial Phase IIB trial of Woke’s psilocybin drug candidate, WP002, to treat chronic musculoskeletal pain. The Principal Investigator, Dr Rob Schütze, is a Research Fellow at the School of Physiotherapy at Curtin University.
“Dr Schütze and Curtin University have established a first-rate team with expertise in psychedelics and chronic pain. Studies suggest that psychedelics can benefit chronic pain through accelerating psychological and behavioural changes, while potentially having direct effects on pain neurophysiology. This Phase IIB trial will explore whether WP002 could offer a new treatment approach for patients with debilitating pain.”
Swinburne University of Technology is a public research university based in Melbourne, Australia. With outstanding researchers and facilities, specialist institutes and centres, strategic platforms and initiatives, and a focus on high-quality and ethically sound research, Swinburne is ranked among the top 300 research-intensive universities in the world.
Woke and Swinburne University of Technology have signed a Memorandum of Understanding to conduct the Phase IIB trial of WP002 for treatment-resistant depression. The prospective Principal Investigator, Professor Susan Rossell, is a cognitive neuropsychologist and Professorial Research Fellow at Swinburne’s Centre for Mental Health.
“Swinburne University of Technology is leading the renaissance of clinical research of psychedelic therapies to treat mental health disorders in Australia. Professor Rossell and her team are well placed to conduct and lead Woke’s flagship Australian Phase IIB trial of WP002 psilocybin-assisted psychotherapy for treatment-resistant depression.”